News tracker · Cited to primary sources

FDA peptide vote 2026: the July PCAC result tracker

Across July 23 to 24, 2026, the FDA's Pharmacy Compounding Advisory Committee recommended six of the seven docketed peptides for the 503A compounding list and rejected one. FDA staff had opposed all seven. It is a recommendation, not a legalization: the FDA still decides, and these stay unapproved for now.

What is PCAC and why does it matter?

PCAC (the Pharmacy Compounding Advisory Committee) is the expert panel that advises the FDA on which bulk substances pharmacies may legally compound under Section 503A. Its vote is a recommendation, not a final rule. The FDA usually follows it but decides on its own. For peptides, this committee is the gatekeeper between “you can get this from a licensed pharmacy” and “gray market only.”

How did the FDA panel vote on each peptide?

7 peptides were on the July 23 to 24 docket, under docket number FDA-2025-N-6895. 4 were reviewed on July 23 and the remaining 3 on July 24. Here is each one with the review day, the evidence grade we assigned it, and how the committee voted. A recommendation to add is a green light to the FDA, not a legal route on its own. It is also not an approval, which is the confusion behind most searches that reach this page. If you are asking whether KPV is an FDA approved peptide, the answer is no, and the same answer covers every row below: a substance can be recommended for the compounding list and still not be an approved drug, because those are two different decisions under two different statutes.

All seven tallies are final. The four recommendations on July 23 and the two on July 24 each passed narrowly, with the committee close to evenly split every time, and DSIP (Delta Sleep-Inducing Peptide) was the only compound the panel declined.

DSIP appears on the FDA agenda under its nominated name, Emideltide. Each substance is docketed in both free-base and acetate form, so the agenda lists fourteen entries for these 7 compounds.

A high grade and a favorable vote are different things. Most of these compounds are Grade D (animal studies only), so an FDA “yes” on the recommendation would make them legally compoundable, not proven to work. See how each grade is assigned on how we grade evidence.

Checking back for the ruling? Get it emailed the day it lands so you do not have to.

How did we get here?

In April 2026 the FDA published a reclassification (Federal Register docket FDA-2025-N-6895) that removed a group of peptides from the 503A Category 2 bulk-substances list, moving them into limbo pending review. That reclassification, plus the political attention around peptides in 2026, is what put these seven compounds in front of PCAC this July. Until the FDA acts on the panel's recommendation, any clinic openly selling the removed peptides is a compliance red flag, not a legal source.

What happens next now that the panel has recommended six of seven?

The decision moves to the FDA. The agency reviews the committee's recommendation and decides whether to add each peptide to the 503A bulks list. There is no fixed deadline, and the FDA is free to agree, decline, or add a compound with conditions. How long that has taken the last two times is measured further down. Two outcomes are on the table:

Neither outcome has anything to do with whether a peptide is approved somewhere else. A compound can be a licensed drug in another country and still be research-only here, because FDA approval and foreign approval are separate registrations: the cerebrolysin FDA approval status is the clearest case on this site, an approved drug in several countries with real randomized human trials behind it, and no legal supervised US route regardless. The same trap catches a compound the panel actually recommended: readers asking whether the FDA approved Semax in the United States are asking about a drug approved in Russia whose US status the July vote left exactly where it was.

How long does the FDA take to act on a PCAC recommendation?

Nobody can give you a date, and anyone who does is guessing. What can be measured is the agency's own record. Adding a substance to the 503A list takes a full notice-and-comment rulemaking, and the FDA has run that rulemaking exactly twice. Here is how long each one took, read from the Federal Register on August 1, 2026:

The round that finished took 2 years 2 months from proposed rule to final rule, and the final rule then took effect 30 days after publication. Placed six bulk substances on the list and identified four the agency considered and did not include. That is the complete precedent for what the FDA is now being asked to do with the peptides this panel recommended.

The second round is the more useful one, because it never finished. The FDA proposed it on September 5, 2019, comments closed on December 4, 2019, and 6 years 10 months later the docket still holds that single proposed rule and no final rule at all. We checked the docket itself on August 1, 2026. A proposed rule is not a deadline, and the agency is under no obligation to ever issue the final one.

The July peptides are not yet at step one of that process. On August 1, 2026, 8 days after the panel finished voting, we queried the Federal Register for every FDA document mentioning bulk drug substances published since the month of the vote. It returned count: 0. Widening the search to any FDA document mentioning peptides since the vote returns one notice, a product-specific guidances availability notice under Docket FDA-2007-D-0369, unrelated to compounding. No proposed rule exists, so the clock in the table above has not started.

What happens next, and where should you actually be watching?

The section above measures the formal route, and that route is the one the FDA would normally take. It is not the one compounding counsel expects. Jesse Dresser, partner at the law firm Frier Levitt, who represents compounding pharmacies and others in the industry, told NPR on August 3, 2026 that formal rulemaking here would run several months to possibly over a year, and then said this:

“It would actually surprise me if this followed the traditional pathway of formal rulemaking. Whatever options exist to make this a faster process, I think they are going to be leveraged.”

That matters for this page specifically. If you are watching the Federal Register for a proposed rule, you may be watching the one channel the industry expects to be bypassed. Below are the three routes named by practising counsel in that reporting. They are attributed possibilities, not outcomes, and not forecasts we are making. Nothing on this list has happened, and none of them is legal access until the FDA itself acts.

1. Route 1

   Interim placement on the Category One list

   The FDA green-lights the peptides in the interim by placing them on the Category One list, giving compounding pharmacies cover to begin making them while the longer rulemaking plays out.

   NPR reports this as the likely scenario. It would be an interim step, not a completed rulemaking, so the formal process would still have to run behind it.

   Named by Jesse Dresser, partner at Frier Levitt, in NPR, August 3, 2026.

2. Route 2

   The Health Secretary acts directly

   Health Secretary Robert F. Kennedy Jr. cites the dangers of the unregulated peptide market as the rationale to immediately place the peptides on a list that permits their compounding.

   “this is a unique scenario, unique product, unique industry and unique administration”

   Dresser says this route would almost certainly draw a legal challenge, because the authority involved is normally used to remove unsafe products from the market rather than to fast-track them.

   Named by Jesse Dresser, partner at Frier Levitt, in NPR, August 3, 2026.

3. Route 3

   The FDA declines to follow its own panel

   The agency bucks the committee's recommendations and leaves the status of the peptides unchanged.

   “In many ways, the toothpaste is out of the tube here. I think that is absolutely part of the calculus.”

   Kundi says this would likely bring lawsuits from the industry, while adding that the agency is clearly attuned to how widely available these products already are.

   Named by Abha Kundi, attorney at ArentFox Schiff, focused on FDA regulatory law, in NPR, August 3, 2026.

One voice in that reporting is neither industry nor advocacy. Ilisa Bernstein, former FDA official and pharmacist, an expert on drug and pharmacy policy, put the constraint this way: “I do think that there is significant pressure here, but the FDA needs to follow the data.” She also named what makes the decision consequential either way: “Once the door is open, any pharmacy can compound these products. So it could have a huge presence in the marketplace.”

A green light is not a shelf date

Even after a green light, pharmacies need time to acquire the active ingredients before they can begin compounding. Scott Brunner, chief executive of the industry trade group the Alliance for Pharmacy Compounding, put that lag at two months to nine monthsdepending on the substance: “It's going to create some chaos. It might take two months, it might take nine months, it depends on the substance.” So even the fastest of the routes above ends in a wait, and any countdown that stops at the FDA decision is stopping early. These will also be prescription products from compounding pharmacies, not something to pick up at a retail chain.

What is actually on the federal calendar, as of August 17, 2026

Rather than assume, we query the Federal Register and print what comes back, with the query. Read 25 days after the July 23, 2026 vote:

An absence in the Federal Register is not proof that nothing is happening. It is proof that nothing has been published, which is a different and narrower claim. Two of the three routes above would not begin with a proposed rule at all, so this check can stay empty right up until the status changes.

Does this new FDA peptide notice change what pharmacies can compound?

There is a second regulatory track for peptides, and it runs separately from the compounding question this page tracks. It is the generic-drug approval pathway, and the FDA acted on it recently. On July 29, 2026 the agency published Product-Specific Guidances; Revised Draft Guidances for Industry; Availability, document 2026-15285, 91 FR 47834, under docket FDA-2007-D-0369. That track concerns whether a company may market a generic copy of an already-approved peptide drug. It is a different question from whether a pharmacy may compound one, and it is worth tracking on its own terms.

The notice withdraws an older guidance, ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin, issued May 2021. That guidance had described when a generic synthetic peptide could reference a listed drug made by recombinant DNA (rDNA) methods. The agency's stated reason for pulling it is that “ it no longer reflects FDA's current scientific thinking.” Its stated plan is: “As noted in the Center for Drug Evaluation and Research guidance agenda, FDA plans to revise and reissue the guidance this year.” So the withdrawal is not the end of the matter; the FDA has said it intends to replace the guidance rather than simply drop it. Comments on the notice close September 28, 2026.

Two different statutes are in play. Generic approval runs under the abbreviated new drug application pathway, 21 U.S.C. 355(j), which governs whether a company may market a generic version of an approved drug. Compounding runs under 21 U.S.C. 353a, the 503A track, which governs whether a pharmacy may make a drug from a bulk substance. The PCAC vote this page tracks sits on that second track. Nothing in this generic-drug notice changes what a compounding pharmacy may lawfully make. On August 2, 2026 we ran both queries side by side: FDA documents mentioning synthetic peptides this year returned count: 1, this notice, while FDA documents on bulk drug substances since the month of the vote still returned count: 0.

The withdrawal is not stated in the notice's abstract. It appears only in the body, in section I, Background. We found it by reading the published full text. A reader who trusts a headline, or the notice's own summary of itself, would not learn that a peptide guidance was pulled at all. That is why this tracker reads the source document rather than the summary, and why a quiet withdrawal can still be a real regulatory event.

The same notice also makes available revised draft bioequivalence guidances for a table of active ingredients. Some of those are compounds this site already grades, including liraglutide, semaglutide and tirzepatide. None of them is one of the peptides the PCAC voted on. The overlap is worth noting, so a reader is not surprised to see familiar names, but it does not connect the two tracks or carry over to the compounding question.

Which peptides are on the next FDA docket?

The next five are already named, and that is the whole advantage of knowing now. After the April 2026 Category 2 removals, reporting pointed to a second PCAC meeting before February 2027 covering GHK-Cu, Selank, Ipamorelin, LL-37 (Cathelicidin) and Melanotan-2 (MT-2), with GHK-Cu named in its injectable form. Reported is the operative word. We queried the Federal Register's own database on August 1, 2026 for FDA notices on bulk drug substances, newest first, and nothing has been published since the July 23 to 24, 2026vote. There is no docket number for the next meeting, no notice, and no date beyond “before February 2027.” The notice that set up July, docket FDA-2025-N-6895, is still the last word on which peptides get reviewed.

Reported watch list, not a confirmed docket. Grades and legal status are read from our peptide records and are current today.

Two things are worth knowing before that meeting, because they will not be in the headlines.

LL-37 is the one on this list carrying real human trial data, and it cuts both ways. A phase 1/2a randomized placebo-controlled study in venous leg ulcers, n=34, found lower doses of topical LL-37 healed several-fold faster than placebo. The larger phase 2b multicentric RCT, n=148, was negative on its primary endpoint, with only a post-hoc signal in patients who had large ulcers. A positive small trial and a failed larger one is a mixed record.

The FDA's openFDA database already holds a recall history for two of the five: 18 records for Ipamorelin and 2 for GHK-Cu (copper peptide), read on 2026-07-31 against a database last updated 2026-07-22. Those counts overlap for combination products, so they can never be added together. And a low count is not a clean safety record. A recall is an action against a regulated manufacturer, so a compound no licensed pharmacy may lawfully make cannot generate one in the first place. The full peptide recall record.

Nothing about these five changes because of a future meeting. Each keeps the legal status our records already carry for it, and a recommendation would not change that either. 21 U.S.C. 353a(c)(1) requires the FDA to convene and consult the advisory committee before it issues the regulations that add a substance to the 503A list, which puts every vote, including this one, upstream of the rulemaking. We add each outcome here as the meeting is noticed and voted. For the legal framework behind all of it, see are peptides legal?